Syntis Bio Closes $38 Million Financing to Accelerate Oral Therapies for Obesity and Rare Diseases

Syntis Bio完成3800万美元融资，加速肥胖症和罕见病口服疗法的发展

Oversubscribed Series A financing led by Cerberus Ventures, with participation from multiple new and existing investors, totals $33 million

由地狱犬创投领投，多位新老投资者参与的 A 轮超额认购融资总计达 3300 万美元。

Syntis also awarded up to $5 million in non-dilutive grants from NIH

Syntis还获得了NIH颁发的最高500万美元的非稀释性拨款

Capital supports SYNT™ platform advancement, including lead SYNT-101 obesity program and SYNT-202 for rare pediatric disorder homocystinuria

资本支持SYNT™平台的发展，包括主导的SYNT-101肥胖症项目和针对罕见儿科疾病高胱氨酸尿症的SYNT-202。

Chenny Zhang of Cerberus Ventures and Michael Nannizzi of W. R. Berkley join Board of Directors

Cerberus Ventures的张晨妮和W. R. Berkley的迈克尔·南尼兹加入董事会。

BOSTON, July 1, 2025-- Syntis Bio, Inc. (Syntis), a clinical-stage biopharmaceutical company revolutionizing oral therapies for obesity, diabetes and rare diseases, announced today the close of a $33 million oversubscribed Series A financing. Cerberus Ventures led the round, with participation from new investors Mansueto Investments, Woori Venture Partners and Apollo Labs.

波士顿，2025年7月1日——Syntis Bio, Inc.（简称Syntis），一家致力于革新肥胖症、糖尿病及罕见病口服疗法的临床阶段生物制药公司，今日宣布完成了3300万美元超额认购的A轮融资。本轮融资由Cerberus Ventures领投，新投资者Mansueto Investments、Woori Venture Partners和Apollo Labs参与跟投。

Founding investors BOLD Capital Partners, W. R. Berkley Corporation, Safar Partners, Portal Innovations, Colorcon Ventures and Cerity Partners Ventures also participated. Syntis has also secured up to $5 million in non-dilutive funding from the National Institutes of Health (NIH) through two Fast-Track Small Business Innovation Research (SBIR) awards from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), supporting the advancement of its SYNT™ (SYNthetic Tissue-lining) platform..

创始投资者BOLD资本合伙公司、W.R.伯克利公司、萨法尔合伙公司、门户创新公司、Colorcon Ventures和Cerity Partners Ventures也参与其中。Syntis还通过国家糖尿病、消化和肾脏疾病研究所（NIDDK）的两项快速通道小型企业创新研究（SBIR）奖项，从美国国立卫生研究院（NIH）获得了高达500万美元的非稀释性资金，以支持其SYNT™（合成组织衬里）平台的发展。

Capital from the Series A financing and grant funding will advance development of SYNT, an orally delivered, transient polymer coating for the small intestine that controls nutrient uptake, enhances gut-restricted enzyme efficacy and increases systemic drug absorption for up to 24 hours. The funding also enables the advancement of lead program SYNT-101 through Phase 1 studies as a once-daily treatment for obesity, as well as initiation of Phase 1 studies for SYNT-202, a first-in-class oral enzyme therapy for homocystinuria, a rare pediatric amino acid disorder.

A轮融资和资助资金将推动SYNT的开发，这是一种口服递送的小肠瞬时聚合物涂层，能够控制营养吸收、增强肠道限制性酶的功效，并在长达24小时内提高全身药物吸收。这笔资金还将推动先导项目SYNT-101进入一期临床试验，作为每日一次的肥胖症治疗方案，同时也将启动SYNT-202的一期临床试验，这是一种针对罕见儿科氨基酸疾病高胱氨酸尿症的首创口服酶疗法。

To date, SYNT-101 has demonstrated strong pre-clinical safety and weight loss data, as well as clinical advancements in safety, mechanism of action and pathways for controlling weight..

迄今为止，SYNT-101 已显示出强大的临床前安全性和减重数据，以及在安全性、作用机制和控制体重途径方面的临床进展。

“We’re grateful for the continued support and enthusiasm of our new and existing investors, who share our vision to revolutionize both chronic and rare disease treatment through safe, effective oral therapies,” said Rahul Dhanda, CEO and co-founder of Syntis Bio. 'This oversubscribed Series A round coupled with these non-dilutive grants validates and accelerates the promise of SYNT-101 in obesity and, more broadly, our SYNT platform technology to unlock the small intestine’s full therapeutic potential to meaningfully improve human health.”.

“我们感谢新老投资者的持续支持和热情，他们与我们有着共同的愿景，即通过安全、有效的口服疗法彻底改变慢性病和罕见病的治疗，”Syntis Bio首席执行官兼联合创始人拉胡尔·丹达表示。“此次超额认购的A轮融资以及这些非稀释性资助，不仅验证了SYNT-101在肥胖症领域的潜力，也加速了其发展。更广泛地说，我们的SYNT平台技术旨在充分释放小肠的治疗潜力，从而显著改善人类健康。”

Syntis also announced the addition of two members to the company’s Board of Directors, Chenny Zhang, director at Cerberus Ventures, and Michael Nannizzi, director of investments at W. R. Berkley. Mr. Dhanda added, “I’m thrilled to welcome Chenny and Michael to our board. Michael has actively advised Syntis since our early days, reflecting W.

Syntis还宣布公司董事会新增两名成员，分别是Cerberus Ventures的董事张晨妮和W. R. Berkley的投资总监迈克尔·南尼齐。Dhanda先生补充道：“我非常高兴欢迎张晨妮和迈克尔加入我们的董事会。自成立以来，迈克尔一直为Syntis提供积极的建议，体现了W. R. Berkley的支持。

R. Berkley’s consistent strategic support, and adding Chenny augments the strong foundation we have built. Her extensive life sciences experience at Cerberus Ventures and previously at In-Q-Tel will be invaluable as Syntis Bio enters our next growth phase focused on strategic partnerships and platform innovation.”.

R. Berkley始终如一的战略支持，以及Chenny的加入进一步增强了我们建立的强大基础。她在Cerberus Ventures和之前在In-Q-Tel的广泛生命科学经验，将为Syntis Bio进入以战略合作伙伴关系和平台创新为重点的下一增长阶段提供巨大价值。”

“While high-cost, complex development processes continue to limit many Americans’ access to essential medicines, Syntis’ SYNT platform represents a fundamentally novel approach to the oral delivery of biologics. We believe SYNT, with its breakthrough technology and platform potential, is poised to significantly expand patient access and redefine what is possible in drug delivery,” said Ms.

“虽然高成本、复杂的开发过程继续限制许多美国人获得基本药物，Syntis的SYNT平台代表了一种从根本上全新的生物制品口服递送方法。我们认为，凭借其突破性技术和平台潜力，SYNT将显著扩大患者获取渠道，并重新定义药物递送的可能性，”女士说道。

Zhang. “I look forward to working closely with the team to realize the full potential of their disruptive platform and pipeline.”.

张表示：“我期待与团队密切合作，充分释放其颠覆性平台和产品线的潜力。”

About SYNT-101

关于SYNT-101

SYNT-101 is being developed as a once-daily pill for the treatment of obesity. SYNT-101 works by transiently blocking nutrient absorption in the duodenum, the upper part of the small intestine, and redirecting nutrients to the distal small intestine to stimulate the natural secretion of satiety and metabolism-regulating hormones, including GLP-1.

SYNT-101 正在被开发为一种每日一次的口服药物，用于治疗肥胖症。SYNT-101 通过暂时阻断十二指肠（小肠的上部）对营养物质的吸收，并将营养物质重新导向到小肠远端，以刺激包括 GLP-1 在内的饱腹感和代谢调节激素的自然分泌。

This mechanism, known as duodenal nutrient exclusion, is a key contributor to the efficacy of gastric bypass surgery, which remains the gold standard for weight loss and metabolic disease management. Recent preclinical data demonstrated 100% preservation of lean muscle mass with consistent 1% weekly weight loss in rodent models, while first-in-human data showed that SYNT-101 demonstrated strong evidence of nutrient redirection and satiety hormone modulation.

这种机制被称为十二指肠营养排除，是胃旁路手术疗效的关键贡献因素，而胃旁路手术仍然是减重和代谢疾病管理的黄金标准。最近的临床前数据显示，在啮齿动物模型中，瘦肌肉质量得以100%保留，并且体重每周稳定下降1%；而首次人体试验数据表明，SYNT-101显示出强烈的营养重分配和饱腹感激素调节的证据。

Importantly, SYNT-101 displayed strong safety and tolerability across both studies, with no adverse events reported..

重要的是，SYNT-101 在两项研究中均显示出良好的安全性和耐受性，且未报告任何不良事件。

About SYNT™ Technology

关于SYNT™技术

SYNT-101 leverages the power of SYNT™ (SYNthetic Tissue-lining) oral therapeutic technology that optimizes therapeutic effects in the small intestine, the body’s nexus for metabolic control, digestion and drug absorption. SYNT uses mussel-inspired polymer chemistry to deliver a safe, transient polydopamine coating to catalase-rich tissues, like the duodenum.

SYNT-101利用了SYNT™（合成组织衬里）口腔治疗技术的力量，该技术优化了小肠内的治疗效果，而小肠是人体代谢控制、消化和药物吸收的核心。SYNT采用受贻贝启发的聚合物化学技术，为富含过氧化氢酶的组织（如十二指肠）提供安全、短暂的聚多巴胺涂层。

After successful deployment in the gastrointestinal tract, the polydopamine lining is sustained for up to 24 hours, after which it is naturally and safely cleared from the body. SYNT is highly versatile and can achieve a variety of therapeutic effects. In addition to nutrient exclusion, SYNT can be engineered to install and sustain gut-restricted enzymes in the small bowel, enhance the oral bioavailability of drugs, and target new tissues throughout the body.

在胃肠道成功部署后，聚多巴胺内衬可以持续长达24小时，之后会自然且安全地从体内清除。SYNT具有高度的通用性，能够实现多种治疗效果。除了营养物质排除之外，SYNT还可以被设计用于在小肠中安装和维持肠道限制性酶、提高药物的口服生物利用度，并靶向作用于全身的新组织。

Data from more than 100 preclinical pig studies conducted by MIT and Syntis demonstrate that SYNT can achieve 70% glucose blocking, 20 times improved enzyme activity, and 4-10 times increased oral drug bioavailability..

麻省理工学院和Syntis进行的100多项临床前猪研究表明，SYNT可实现70%的葡萄糖阻断、酶活性提升20倍、口服药物生物利用度提高4至10倍。

About Syntis Bio

关于Syntis Bio

Syntis Bio is a clinical-stage biopharmaceutical company developing oral therapies that harness the small intestine’s unique biology to provide more accessible, effective and sustainable solutions across the healthcare spectrum, from rare genetic disorders to the world’s most prevalent conditions. Syntis is rapidly advancing a pipeline of oral therapies engineered for targeted activity in the small intestine, the body’s nexus for metabolic control, digestion and drug absorption.

Syntis Bio是一家临床阶段的生物制药公司，致力于开发口服疗法，利用小肠的独特生物学特性，为从罕见遗传病到全球最普遍的疾病提供更易获取、更有效且可持续的医疗解决方案。Syntis正在快速推进一系列针对小肠活动的口服疗法管线，小肠是人体代谢控制、消化和药物吸收的核心。

Alongside its lead obesity program, SYNT-101, the company is advancing a portfolio of therapies targeting orphan metabolic diseases and intestinal-related disorders. Syntis is headquartered in Boston, MA. For more information, please visit www.syntis.bio and follow us on LinkedIn..

除了其主要的肥胖症项目SYNT-101外，该公司还在推进一系列针对罕见代谢疾病和肠道相关疾病的治疗方案。Syntis总部位于马萨诸塞州波士顿。欲了解更多信息，请访问www.syntis.bio并在LinkedIn上关注我们。

NIH Grant Acknowledgment

NIH 资助致谢

Research reported in this press release was supported by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health under Award Numbers R44DK138869 and R44DK141341. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health..

本新闻稿中报道的研究得到了美国国立卫生研究院糖尿病、消化和肾脏疾病国家研究所的支持，资助编号为R44DK138869和R44DK141341。内容完全由作者负责，不一定代表美国国立卫生研究院的官方观点。

Contact:

联系：

Media Contact:

媒体联系人:

Dan Budwick, 1AB

丹·布德威克，1AB

dan@1abmedia.com

dan@1abmedia.com

Investor Contact:

投资者联系方式：

IR@syntis.bio

IR@syntis.bio